My Profile

Search abstracts

Lewis Sheiner


2018
Montreux, Switzerland



2017
Budapest, Hungary

2016
Lisboa, Portugal

2015
Hersonissos, Crete, Greece

2014
Alicante, Spain

2013
Glasgow, Scotland

2012
Venice, Italy

2011
Athens, Greece

2010
Berlin, Germany

2009
St. Petersburg, Russia

2008
Marseille, France

2007
KÝbenhavn, Denmark

2006
Brugge/Bruges, Belgium

2005
Pamplona, Spain

2004
Uppsala, Sweden

2003
Verona, Italy

2002
Paris, France

2001
Basel, Switzerland

2000
Salamanca, Spain

1999
Saintes, France

1998
Wuppertal, Germany

1997
Glasgow, Scotland

1996
Sandwich, UK

1995
Frankfurt, Germany

1994
Greenford, UK

1993
Paris, France

1992
Basel, Switzerland



Printable version

PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe.
ISSN 1871-6032

Reference:
PAGE 25 (2016) Abstr 5794 [www.page-meeting.org/?abstract=5794]


Poster: Methodology - Study Design


III-01 Giulia Lestini Model-based optimal robust design in pharmacometrics

Giulia Lestini, Sebastian Ueckert, France Mentrť

IAME, UMR 1137, INSERM, University Paris Diderot, Paris, France

Objectives: Optimal design requires prior information on models and parameters, which may be difficult to guess. Robust design approaches have been developed for taking into account the uncertainty of parameters [1,2]. Our aims were i) to compare various robust design criteria for design in nonlinear mixed effect models (NLMEM) for a PKPD example with continuous data; ii) to evaluate robust designs using a new method for the evaluation of the Fisher information matrix (FIM) for a NLMEM with discrete data.

Methods: The PKPD model was already used for evaluation of adaptive design [3]. We studied robust design assuming prior distributions for two PD parameters kout and IC50, keeping the PK fixed as in [3]. For 50 patients, 3 sampling times were optimized using D-optimality and the following robust criteria: ED (Expectation of Determinant of FIM), EID (Expectation of the Inverse Determinant), ELD (Expectation of log Determinant), and max-min (minimum of determinant). Predicted relative standard errors (pRSE) for 1000 simulated set of parameters were used for designs comparison.

A logistic model for repeated binary response [4] was defined with treatment increasing the slope of the logit of the response with time. Design evaluation was performed using a new method to compute FIM based on Adaptive Gaussian Quadrature and Quasi Random Monte Carlo[5,6]. We evaluated an equispaced design (ξES) of 4 sampling times, with 50 patients per arm. We then optimized the two intermediate times (fixing the first and the last) using standard D-optimality (ξD) or using the robust ELD criterion (ξELD) with prior uncertainties on the slope and treatment effect

Results: For the PKPD example, the different robust criteria led to different optimal designs. ξELD performed the best in terms of pRSE across the 1000 simulations, the worst was ξmax-min. For IC50 the 90% percentiles for pRSE were 26% for ξELD and 64% for ξmax-min.

The evaluation of FIM with the new approach is rather fast, allowing for the first time robust design optimization for discrete longitudinal models. ξD and ξELD were very close. ξES has a loss of efficiency of 0.82 compare to ξD. When prior uncertainty is assumed, the loss of efficiency is 0.66 compared to ξELD.

Conclusions: Robust designs criteria showed better performance of ξELD in NLMEM. Robust and optimal designs are also useful in the context of binary response studies, providing better results than equispaced design.

This work was supported by the DDMoRe project (www.ddmore.eu).



References:
[1] Dodds MG, Hooker AC, Vicini P. Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn. 2005 Feb;32(1):33–64.
[2] Foo L-K, Duffull S. Methods of Robust Design of Nonlinear Models with an Application to Pharmacokinetics. J Biopharm Stat. 2010 May 19;20(4):886–902.
[3] Lestini G, Dumont C, Mentré F. Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology. Pharm Res. 2015 Oct;32(10):3159–69.
[4] Ogungbenro K, Aarons L. Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments. J Pharmacokinet Pharmacodyn. 2011 Aug;38(4):449–69.
[5] Ueckert S, Mentré F. Computation of the Fisher information matrix for discrete nonlinear mixed effect models. 8th International Conference of the ERCIM WG on Computational and Methodological Statistics (CMStatistics) University of London, UK. 2015.
[6] Ueckert S, Mentré F. Computation of the Fisher information matrix for discrete non-linear mixed effect models. Population Optimum Design of Experiments (PODE) Isaac Newton Institute for Mathematical Sciences, Cambridge. 2015.